MediciNova Completes Double-Blind Phase of ALS Trial, Topline Data Due by Year-End
MNOV has more than doubled off its 52-week low of $1.168.
Summary
MediciNova has completed the last patient, last visit in the double-blind portion of its Phase 2b/3 COMBAT-ALS trial of MN-166, with topline results expected by end-2026. The trial randomized 234 participants and uses the clinically meaningful CAFS composite as the primary endpoint. This milestone de-risks the timeline and sets a defined catalyst window for data readout. The company also has FDA Fast Track and Orphan designations, which could expedite review if results are positive. Full study LPLV is expected in March 2027, with an open-label extension ongoing for longer-term safety.
At the time of this announcement, MNOV was trading at $2.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $137.8M. The 52-week trading range was $1.17 to $3.90. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.